Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C67079
http://purl.obolibrary.org/obo/NCIT_C67079
|
|---|---|
| Preferred Name | Rilotumumab |
| Definitions |
A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody AMG 102 binds to and neutralizes HGF, preventing the binding of HGF to its receptor c-Met and so c-Met activation; inhibition of c-Met-mediated signal transduction may result in the induction of apoptosis in cells expressing c-Met. c-Met (HGF receptor or HGFR), a receptor tyrosine kinase overexpressed or mutated in a variety of epithelial cancer cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody AMG 102 binds to and neutralizes HGF, preventing the binding of HGF to its receptor c-Met and so c-Met activation; inhibition of c-Met-mediated signal transduction may result in the induction of apoptosis in cells expressing c-Met. c-Met (HGF receptor or HGFR), a receptor tyrosine kinase overexpressed or mutated in a variety of epithelial cancer cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis. |
|---|---|
| prefLabel | Rilotumumab
|
| label | Rilotumumab
|
| PDQ_Closed_Trial_Search_ID | 536240
|
| code | C67079
|
| Has_Target | |
| prefixIRI | NCIT:C67079
|
| in_subset |
See more
See less
|
| Display_Name | Rilotumumab
|
| Preferred_Name | Rilotumumab
|
| FDA_UNII_Code | 51WEW898IJ
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Rilotumumab
|
| CAS_Registry | 872514-65-3
|
| NCI_Drug_Dictionary_ID | 536240
|
| Legacy Concept Name | Anti-HGF_Monoclonal_Antibody_AMG_102
|
| type | |
| ALT_DEFINITION | A substance being studied in the treatment of cancer. It binds to a protein called hepatocyte growth factor (HGF), which may cause cancer cells to grow. Blocking this may cause cancer cells to die. AMG 102 is a type of monoclonal antibody.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 536240
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C2743963
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |